Mab

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 9, 2023

Additionally, we look forward to progressing AVTX-008, our BTLA agonist fusion protein with high-binding affinity and serum stability, to IND.

Key Points: 
  • Additionally, we look forward to progressing AVTX-008, our BTLA agonist fusion protein with high-binding affinity and serum stability, to IND.
  • The Company previously announced it entered into a purchase agreement with AUG to divest the 800 Series on September 12, 2023.
  • Third Quarter 2023 Financial Update:
    Avalo had $10.2 million in cash and cash equivalents as of September 30, 2023.
  • The Company raised $46.2 million of net proceeds from equity financings in the nine months ended September 30, 2023.

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023

“The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Key Points: 
  • “The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • Finally, we presented the first ever comprehensive data on CRB-913, our highly peripherally restricted cannabinoid type-1 receptor (CB1) inverse agonist.
  • Early clinical experience will be shared in Q1 2024, which will coincide with the initiation of a U.S./EU trial by Corbus.
  • Corbus presented two posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held on November 1 - 5, 2023.

Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Friday, November 3, 2023

LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTCQB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023.

Key Points: 
  • OTCQB companies must be current in their financial reporting and undergo an annual verification and management certification process.
  • We remain optimistic of successful outcomes from these efforts in the coming months,” commented Vu Truong, Ph.D., Chief Executive Officer of Aridis Pharmaceuticals.
  • Due to fair value option valuation of our notes payable, there was no interest expense recorded during the third quarter of 2023.
  • Other Income: Other income increased to $26,000 for the quarter ended September 30, 2023, compared to approximately $23,000 for the quarter ended September 30, 2022.

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Retrieved on: 
Friday, November 3, 2023

BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported initial data from the monotherapy dose-escalation portion of its Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation). The data, to be presented in a late-breaker poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, suggest a potential best-in-class safety and pharmacokinetic profile among VISTA blocking antibodies and the potential to overcome long-standing pharmacological challenges encountered by first generation approaches to blocking VISTA.

Key Points: 
  • “We are pleased to report favorable clinical data for SNS-101, a pioneering VISTA-blocking antibody that provides validation of our conditionally active approach.
  • Summary of reported data (as of the October 3, 2023 cutoff date):
    A total of 13 patients were enrolled in the study.
  • There were no instances of cytokine release syndrome and no significant changes in key inflammatory cytokines over time, consistent with preclinical studies.
  • Pharmacokinetic data demonstrate dose-proportional exposure consistent with lack of target mediated drug disposition, no notable accumulation with repeat dosing, and linear elimination kinetics of SNS-101, in concordance with preclinical data.

Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control

Retrieved on: 
Friday, November 3, 2023

Phio’s innovative preclinical study data highlights the benefit of intratumoral injection (IT) of an INTASYL compound targeting CTLA-4 (27790) in conjunction with systemic anti-PD-1 antibody therapy.

Key Points: 
  • Phio’s innovative preclinical study data highlights the benefit of intratumoral injection (IT) of an INTASYL compound targeting CTLA-4 (27790) in conjunction with systemic anti-PD-1 antibody therapy.
  • The combination of INTASYL compound 27790 with systemic anti-PD-1 antibody therapy significantly enhanced the efficacy of anti-PD-1 mAb therapy in vivo.
  • Additionally, INTASYL compound 27790 appeared to improve the efficacy of anti-PD-1 therapy toward those tumors not treated directly with 27790.
  • INTASYL compound 27790 increased the percentage of reactive CD8+ T cells in the tumor while decreasing immunosuppressive/pro-tumor macrophages in the treated tumor micro-environment.

Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease

Retrieved on: 
Monday, November 6, 2023

SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals that provides Acumen access to Halozyme's ENHANZE® drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery, for a single target. Acumen intends to explore the potential use of ENHANZE® for ACU193, Acumen's clinical-stage monoclonal antibody (mAb) candidate to target Amyloid-β Oligomers (AβOs) for the treatment of early Alzheimer's disease (AD).

Key Points: 
  • Under the terms of the agreement, Acumen will make an upfront payment to Halozyme, and potential future milestone payments related to development progress, regulatory approvals, and sales attainment.
  • Halozyme will also be entitled to single digit royalties on net sales of commercialized medicines with the ENHANZE® technology.
  • ACU193 has been granted Fast Track designation for the treatment of early Alzheimer's disease by the U.S. Food and Drug Administration.
  • This deal marks Halozyme's thirteenth global collaboration and license partner for the ENHANZE® technology.

Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

Retrieved on: 
Thursday, October 26, 2023

Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services for Hope Medicine's first-in-class monoclonal antibody drug, HMI-115.

Key Points: 
  • Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services for Hope Medicine's first-in-class monoclonal antibody drug, HMI-115.
  • Hope Medicine will leverage Chime Biologics' extensive experience in 2000L cGMP manufacturing, late-stage CMC development and BLA filings to jointly accelerate HMI-115 mAb development and manufacturing for speedy clinical advancement of targeting endometriosis and androgenetic alopecia, benefiting more female patients and alopecia patients.
  • Dr. Damian Tu, President of Hope Medicine, said, "HMI-115 is Hope Medicine's most critical and advanced clinical antibody drug asset.
  • Dr. Jimmy Wei, President of Chime Biologics, said, "We are pleased to be a strategic partner of Hope Medicine.

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Retrieved on: 
Wednesday, October 25, 2023

BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it will present initial safety and pharmacokinetic monotherapy clinical data from its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), in a late-breaking poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held in San Diego, Calif., from November 1 - 5, 2023.

Key Points: 
  • BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it will present initial safety and pharmacokinetic monotherapy clinical data from its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), in a late-breaking poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held in San Diego, Calif., from November 1 - 5, 2023.
  • Title: A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
    A copy of the presentation materials will be added to the “Events & Presentations” section of the Company’s Investor Relations website at www.senseibio.com following the presentation.

OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody

Retrieved on: 
Monday, October 23, 2023

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal antibody evaluated in advanced solid tumors, have been presented, at the European Society for Medical Oncology conference , held in Madrid, Spain (October 20 – 24, 2023).

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal antibody evaluated in advanced solid tumors, have been presented, at the European Society for Medical Oncology conference , held in Madrid, Spain (October 20 – 24, 2023).
  • BI 770371 is an IgG1 mAb that recognizes both the V1 and V2 variants of SIRPα.
  • We are very pleased to potentially make our selective SIRPα inhibitor technology available to more patients through this strategic collaboration.
  • The first clinical results of BI 770371 presented at ESMO 2023 conference (Madrid, Abstract #697P ) showed that adverse events were manageable during the on-treatment period, Maximal Tolerated Dose (MTD) has not been reached.

Global Monoclonal Antibody Diagnostic Reagent Market Analysis Report 2023-2028: Increasing Availability of POCT, Growing Use of Multiplexed Assays, & Development Of New mAB Therapies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 18, 2023

The global monoclonal antibody diagnostic reagent market value is projected to grow at a CAGR of 13.25%, during the forecast period of 2023-2028.

Key Points: 
  • The global monoclonal antibody diagnostic reagent market value is projected to grow at a CAGR of 13.25%, during the forecast period of 2023-2028.
  • The market for Monoclonal Antibody Diagnostic Reagents is poised for significant growth, driven by a robust pipeline of monoclonal antibody therapeutics in development.
  • Global Monoclonal Antibody Diagnostic Reagent Market Dynamics:
    Growth Drivers: Monoclonal antibody diagnostic reagents aid in the early identification and accurate diagnosis of many cancers.
  • Global Monoclonal Antibody Diagnostic Reagent Market: An Analysis
    Global Monoclonal Antibody Diagnostic Reagent Market: An Overview
    Global Monoclonal Antibody Diagnostic Reagent Market by Test (Enzyme Linked Immunosorbent, Double Antigen Sandwich Chemiluminescence Method, Assay Recombinant Immunoblot and Dot-immunogold Filtration Assay)
    Global Monoclonal Antibody Diagnostic Reagent Market by Application (Tumor Monitoring, Virus Detection, Hormones Diagnosis and Others)
    Global Monoclonal Antibody Diagnostic Reagent Market by Region (North America, Europe, Asia Pacific and Rest of the World)
    Global Monoclonal Antibody Diagnostic Reagent Market: Tests Analysis
    Global Monoclonal Antibody Diagnostic Reagent Market: Tests Overview
    Global Monoclonal Antibody Diagnostic Reagent Market: Application Analysis
    Global Monoclonal Antibody Diagnostic Reagent Market: Application Overview